Printer Friendly Version
Printer Friendly Version
Printer Friendly Version
A.2.02.08
Various devices are available for outpatient cardiac rhythm monitoring. These devices differ in the types of monitoring leads used, the duration and continuity of monitoring, the ability to detect arrhythmias without patient intervention, and the mechanism of delivering the information from patient to clinician.These devices may be used to evaluate symptoms suggestive of arrhythmias (eg, syncope or palpitations), and may be used to detect atrial fibrillation (AF) in patients who have undergone cardiac ablation of AF or who have a history of cryptogenic stroke.
Cardiac Arrhythmias
Cardiac monitoring is routinely used in the inpatient setting to detect acute changes in heart rate or rhythm that may need urgent response. For some conditions, a more prolonged period of monitoring in the ambulatory setting is needed to detect heart rate or rhythm abnormalities that may occur infrequently. These cases may include the diagnosis of arrhythmias in patients with signs and symptoms suggestive of arrhythmias as well as the evaluation of paroxysmal atrial fibrillation (AF).
Cardiac arrhythmias may be suspected because of symptoms suggestive of arrhythmias, including palpitations, dizziness, syncope or presyncope, or because of abnormal heart rate or rhythm noted on exam. A full discussion of the differential diagnosis and evaluation of each of these symptoms is beyond the scope of this policy, but some general principles on the use of ambulatory monitoring are discussed.
Arrhythmias are an important potential cause of syncope or near syncope, which in some cases may be described as dizziness. An electrocardiogram (ECG) is generally indicated whenever there is suspicion of a cardiac cause of syncope. Some arrhythmic causes will be apparent on ECG. However, for patients in whom an ECG is not diagnostic, longer monitoring may be indicated. The 2009 joint guidelines from the European Society of Cardiology and three other medical specialty societies suggested that, in individuals with clinical or ECG features suggesting an arrhythmic syncope, ECG monitoring is indicated; the guidelines also stated that the “duration (and technology) of monitoring should be selected according to the risk and the predicted recurrence rate of syncope.” Similarly, guidelines from the National Institute for Health and Care Excellence on the evaluation of transient loss of consciousness, have recommended the use of an ambulatory ECG in individuals with a suspected arrhythmic cause of syncope. The type and duration of monitoring recommended is based on the individual’s history, particularly the frequency of transient loss of consciousness. The Holter monitor is recommended if transient loss of consciousness occurs several times a week. If the frequency of transient loss of consciousness is every 1 to 2 weeks, an external event recorder is recommended; and if the frequency is less than once every 2 weeks, an implantable event recorder is recommended.
Similar to syncope, the evaluation and management of palpitations is patient-specific. In cases where the initial history, examination, and ECG findings are suggestive of an arrhythmia, some form of ambulatory ECG monitoring is indicated. A position paper from the European Heart Rhythm Association indicated that, for individuals with palpitations of unknown origin who have clinical features suggestive of arrhythmia, referral for specialized evaluation with consideration for ambulatory ECG monitoring is indicated.
Atrial Fibrillation Detection
AF is the most common arrhythmia in adults. It may be asymptomatic or be associated with a broad range of symptoms, including lightheadedness, palpitations, dyspnea, and a variety of more nonspecific symptoms (eg, fatigue, malaise). It is classified as paroxysmal, persistent, or permanent based on symptom duration. Diagnosed AF may be treated with antiarrhythmic medications with the goal of rate or rhythm control. Other treatments include direct cardioversion, catheter-based radiofrequency- or cryo-energy-based ablation, or one of several surgical techniques, depending on the patient’s comorbidities and associated symptoms.
Stroke in AF occurs primarily as a result of thromboembolism from the left atrium. The lack of atrial contractions in AF leads to blood stasis in the left atrium, and this low flow state increases the risk of thrombosis. The area of the left atrium with the lowest blood flow in AF, and therefore the highest risk of thrombosis, is the left atrial appendage. Multiple clinical trials have demonstrated that anticoagulation reduces the ischemic stroke risk in patients at moderate- or high-risk of thromboembolic events. Oral anticoagulation in patients with AF reduces the risk of subsequent stroke and is recommended by the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society in 2014 joint guidelines on patients with a history of stroke or transient ischemic attack.
Ambulatory ECG monitoring may play a role in several situations in the detection of AF. In patients who have undergone ablative treatment for AF, if ongoing AF can be excluded with reasonable certainty, including paroxysmal AF which may not be apparent on ECG during an office visit, anticoagulation therapy could potentially be stopped. In some cases where identifying paroxysmal AF is associated with potential changes in management, longer term monitoring may be considered. There are well-defined management changes that occur in patients with AF. However, until relatively recently the specific role of long-term (ie, >48 hours) monitoring in AF was not well-described.
Patients with cryptogenic stroke are often monitored for the presence of AF because AF is estimated to be the cause of cryptogenic stroke in more than 10% of patients, and AF increases the risk of stroke. Paroxysmal AF confers an elevated risk of stroke, just as persistent and permanent AF does. In individuals with a high-risk of stroke, particularly those with a history of ischemic stroke that is unexplained by other causes, prolonged monitoring to identify paroxysmal AF has been investigated.
Cardiac Rhythm Ambulatory Monitoring Devices
Ambulatory cardiac monitoring with a variety of devices permits the evaluation of cardiac electrical activity over time, in contrast to a static ECG, which only permits the detection of abnormalities in cardiac electrical activity at a single point in time.
A Holter monitor is worn continuously and records cardiac electrical output continuously throughout the recording period. Holter monitors are capable of recording activity for 24 to 72 hours. Traditionally, most Holter monitors have three channels based on three ECG leads. However, some currently available Holter monitors have up to 12 channels. Holter monitors are an accepted intervention in a variety of settings where a short period (24 to 48 hours) of comprehensive cardiac rhythm assessment is needed (eg, suspected arrhythmias when symptoms [syncope, palpitations] are occurring daily). These devices are not the focus of this policy.
Various classes of devices are available for situations where longer monitoring than can be obtained with a traditional Holter monitor is needed. Because there may be many devices within each category, a comprehensive description of each device is beyond the scope of this policy. Devices vary in how data are transmitted to the location where the ECG output is interpreted. Data may be transmitted via cellular phone or landline, or by direct download from the device after its return to the monitoring center. The device classes are described in the table below.
Ambulatory Cardiac Rhythm Monitoring Devices
Device Class | Description | Device Examples |
Noncontinuous devices with memory (event recorder) | Devices not worn continuously but rather activated by patient and applied to the skin in the precordial area when symptoms develop | Zio® Event Card (iRhythm Technologies) REKA E100™ (REKA Health) |
Continuous recording devices with longer recording periods | Devices continuously worn and continuously record via ≥1 cardiac leads and store data longer than traditional Holter (14 days) | Zio®XT Patch and ZIO ECGUtilization Service (ZEUS) System (iRhythm Technologies) |
External memory loop devices (patient- or autotriggered) | Devices continuously worn and store a single channel of ECG data in a refreshed memory. When the device is activated, the ECG is then recorded from the memory loop for the preceding 30-90 seconds and for next 60 seconds or so. Devices may be activated by a patient when symptoms occur (patient-triggered) or by an automated algorithm when changes suggestive of an arrhythmia are detected (auto-triggered). | Patient-triggered: Explorer™ Looping Monitor (LifeWatch Services) Auto-triggered: LifeStar AF Express™ Auto-Detect Looping Monitor (LifeWatch Services) Auto-triggered or patient-triggered: King of Hearts Express® AF (Card Guard Scientific Survival) |
Implantable memory loop devices (patient- or auto-triggered) | Devices similar in design to external memory loop devices but implanted under the skin in the precordial region | Auto-triggered or patient-triggered: Reveal® XT ICM (Medtronic) and Confirm Rx Insertable™ Cardiac Monitor (Abbott) Auto-triggered: BioMonitor, Biotronik |
Mobile cardiac outpatient telemetry | Continuously recording or auto-triggered memory loop devices that transmit data to a central recording station with real-time monitoring and analysis | CardioNet MCOT™ (BioTelemetry) LifeStar Mobile Cardiac Telemetry (LifeWatch Services) Zio AT (iRhythm) SmartCardia 7L (SmartCardia) |
There are also devices that combine features of multiple classes. For example, the LifeStar ACT Ex Holter (LifeWatch Services) is a 3-channel Holter monitor, but is converted to a mobile cardiac telemetry system if a diagnosis is inconclusive after 24 to 48 hours of monitoring. The BodyGuardian® Heart Remote Monitoring System (Preventice Services) is an external auto-triggered memory loop device that can be converted to a real-time monitoring system. The eCardio Verité™ system (eCardio) can switch between a patient-activated event monitor and a continuous telemetry monitor. The Spiderflash-T (LivaNova) is an example of an external auto-triggered or patient-triggered loop recorder, but like the Zio Patch, can record 2 channels for 14 to 40 days.
Some of the newer devices are described above for informational purposes. However, because there may be many devices within each category, a comprehensive description of individual devices is beyond the scope of this policy.
The use of patient-activated or auto-activated external ambulatory event monitorsOR continuous ambulatory monitors that record and store information for periods longer than 48 hours may be considered medically necessary as a diagnostic alternative to Holter monitoring in the following situations:
Individuals who experience infrequent symptoms (less frequently than every 48 hours) suggestive of cardiac arrhythmias (i.e., palpitations, dizziness, presyncope, or syncope).
Individuals with atrial fibrillation who have been treated with catheter ablation, and in whom discontinuation of systemic anticoagulation is being considered.
Individuals with cryptogenic stroke who have a negative standard work-up for atrial fibrillation including a 24-hour Holter monitor. (See Policy Guidelines)
The use of implantable ambulatory event monitors, either patient-activated or auto-activated, may be considered medically necessaryin the following situations:
In the small subset of individuals who experience recurrent symptoms so infrequently that a prior trial of other external ambulatory event monitors has been unsuccessful.
In individuals who require long-term monitoring for atrial fibrillation or possible atrial fibrillation. (See Policy Guidelines)
The use of outpatient cardiac telemetry (also known as mobile cardiac outpatient telemetry)as a diagnostic alternative to ambulatory event monitors in individuals who experience infrequent symptoms (less frequently than every 48 hours) suggestive of cardiac arrhythmias (ie, palpitations, dizziness, presyncope, or syncope) is considered investigational.
Other uses of ambulatory event monitors, including outpatient cardiac telemetry and mobile applications, are considered investigational, including but not limited to monitoring asymptomatic individuals with risk factors for arrhythmia, monitoring the effectiveness of antiarrhythmic medications, and detection of myocardial ischemia by detecting ST-segment changes.
None
The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.
The available evidence has suggested that long-term monitoring for atrial fibrillation postablation or after cryptogenic stroke is associated with improved outcomes, but the specific type of monitoring associated with the best outcomes is not well-defined. Trials demonstrating improved outcomes have used either event monitors or implantable monitors. In addition, there are individual considerations that may make one type of monitor preferable over another.
Therefore, for the evaluation of individuals with cryptogenic stroke who have had a negative standard workup for atrial fibrillation including 24-hour Holter monitoring, or for the evaluation of atrial fibrillation after an ablation procedure, the use of long-term monitoring with an external event monitor, OR a continuous ambulatory monitor that records and stores information for periods longer than 48 hours, OR an implantable ambulatory monitor may be considered medically necessary for individuals who meet the criteria outlined above.
Medically Necessary is defined as those services, treatments, procedures, equipment, drugs, devices, items or supplies furnished by a covered Provider that are required to identify or treat a Member's illness, injury or Mental Health Disorders, and which Company determines are covered under this Benefit Plan based on the criteria as follows in A through D:
A. consistent with the symptoms or diagnosis and treatment of the Member's condition, illness, or injury; and
B. appropriate with regard to standards of good medical practice; and
C. not solely for the convenience of the Member, his or her Provider; and
D. the most appropriate supply or level of care which can safely be provided to Member. When applied to the care of an Inpatient, it further means that services for the Member's medical symptoms or conditions require that the services cannot be safely provided to the Member as an Outpatient.
For the definition of medical necessity, “standards of good medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. BCBSMS makes no payment for services, treatments, procedures, equipment, drugs, devices, items or supplies which are not documented to be Medically Necessary. The fact that a Physician or other Provider has prescribed, ordered, recommended, or approved a service or supply does not in itself, make it Medically Necessary.
Investigative is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized as a generally accepted standard of good medical practice for the treatment of the condition being treated and; therefore, is not considered medically necessary. For the definition of Investigative, “generally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting.
2/1999: Implantable Continuous "Memory Loop" Devices policy approved by Medical Policy Advisory Committee (MPAC), CPT 33999 added.
5/1999: MPAC expanded and renamed policy to include all Ambulatory Event Monitors.
1/23/2002: Prior authorization deleted.
2/15/2002: Investigational definition added.
4/18/2002: Type of Service and Place of Service deleted.
5/23/2002: Code Reference section updated, CPT 93012, 93014 added.
8/4/2003: Code Reference section updated, HCPCS G0004-G0007, G00015 deleted.
10/21/2004: Code Reference section updated, CPT 33999, 93012, 93014 deleted, CPT 93270, 93271, 93272 description revised, ICD-9 procedure code 86.05, 86.09 description revised, HCPCS G0015 deleted.
10/25/2005: Policy clarified and re-titled.
03/07/2006: Coding updated. HCPCS 2006 revisions added to policy.
09/12/2006: Coding updated. ICD9 2006 revisions added to policy.
1/3/2007: Policy reviewed, policy section clarified.
5/11/2007: Policy reviewed. Policy section updated; no change to policy statements.
12/24/2008: Coding reference section updated per the 2009 CPT/HCPCS revisions.
5/14/2009: Outpatient cardiac telemetry (MCOT) changed from "investigational" to "not medically necessary."
04/12/2010: Description section revised with other outpatient cardiac telemetry systems. Coding Section revised to add CPT Codes 93228 and 93229 and ICD-9 Diagnosis codes 427.0, 427.1, 427.2, 427.31, 427.32, 427.41, 427.42, 427.61, 427.69 and 427.81 to the Covered Codes Table. Also identified HCPCS Codes S0345, S0346 & S0347 were deleted as of 12/31/2009.
10/21/2010: Policy reviewed; no changes.
03/10/2011: Added ICD-9 code 785.0 to the Covered Codes table.
01/17/2012: Added the following policy statement: The use of auto-activated external ambulatory event monitors may be considered medically necessary in patients treated for atrial fibrillation to monitor for asymptomatic episodes in order to evaluate treatment response. Deleted outdated references from the Sources section. Removed deleted HCPCS codes S0345, S0346, and S0347 from the Code Reference section.
02/20/2013: Policy description updated regarding available devices. Policy statement revised to add patients with cryptogenic stroke to the last investigational statement. Added the following policy statement: Continuous ambulatory monitors that record and store information for periods longer than 72 hours are considered investigational. The first policy statement was re-worded to add patient-activated or auto-activated monitors. The policy statement regarding use of event monitors in patients with atrial fibrillation treated with catheter ablation was revised for clarity purposes.
04/22/2014: Policy statement revised to state that continuous ambulatory monitors that record and store information for periods longer than 48 hours are considered investigational. It previously stated longer than 72 hours.
09/22/2014: Added new medically necessary policy statement for patients with cryptogenic stroke who have a negative standard work-up for atrial fibrillation including a 24-hour Holter monitor. Added "to ambulatory event monitors" to the outpatient cardiac telemetry policy statement.
02/02/2015: Policy description updated regarding devices. Removed "Holter monitor" from the policy statement regarding the use of implantable ambulatory event monitors. Revised the following statement: Outpatient cardiac telemetry (also known as mobile cardiac outpatient telemetry or MCOT) as a diagnostic alternative to ambulatory event monitors in patients who experience infrequent symptoms (less frequently than every 48 hours) suggestiveof cardiac arrhythmias (ie, palpitations, dizziness, presyncope, or syncope) are expected to result in outcomes that are equivalent to alternatives such as autotrigger devices, but may be more costly than alternatives. In this situation, the more costly alternative may be considered not medically necessary. Policy statement regarding the use of continuous ambulatorymonitors changed from investigational to medically necessary with certain criteria. Investigational policy statement revised to change "antiarrhythmic therapy" to "antiarrhythmic medications" and remove "for patients with cryptogenic stroke." Policy guidelines updated regarding health outcomes for MCOT and alternative methods.
05/19/2015: Removed ICD-9 procedure codes 86.05, 86.09, and 89.50 from the Code Reference section.
08/14/2015: Medical policy revised to add ICD-10 codes. Added ICD-9 procedure code 37.79 and ICD-9 diagnosis code 434.91 to the Code Reference section.
11/11/2015: Policy description updated regarding devices and technologic advances. Medically necessary policy statement regarding the use of implantable ambulatory event monitors updated to add patients with cryptogenic stroke. Policy statement regarding the use of outpatient cardiac telemetry changed from "not medically necessary" to "investigational." Policy guidelines updated to clarify that for the evaluation of patients with cryptogenic stroke, either the use of an external long term monitor or an implantable monitor (but not both) may be considered medically necessary. Added medically necessary and investigative definitions.
06/06/2016: Policy number A.2.02.08 added.
07/22/2016: Policy description rewritten. Medically necessary policy statements regarding continuous ambulatory monitors with longer recording periods and external ambulatory event monitors combined into one statement. Policy statement updated to state that the use of implantable ambulatory event monitors may be considered medically necessary in patients who require long-term monitoring for atrial fibrillation or possible fibrillation. Policy Guidelines updated regarding long-term monitoring for atrial fibrillation.
08/15/2016: Code Reference section updated to add CPT codes 0295T, 0296T, 0297T, and 0298T.
05/31/2017: Policy description updated regarding devices. Policy statements unchanged.
06/01/2018: Policy description updated regarding devices and atrial fibrillation detection. Last policy statement updated to include the following as examples of other uses of ambulatory event monitors that are considered investigational: 1) mobile applications and 2) monitoring asymptomatic patients with risk factors for arrhythmia.
10/01/2018: Policy description updated regarding devices. Code Reference section updated to add new ICD-10 diagnosis code I63.89.
12/18/2018: Code Reference section updated to add new CPT codes 33285 and 33286, effective 01/01/2019.
06/04/2019: Policy description updated regarding atrial fibrillation detection. Policy statements unchanged.
09/23/2019: Code Reference section updated to add new ICD-10 procedure codes 0JWT0FZ and 0JWT3FZ and ICD-10 diagnosis codes I48.11, I48.19, I48.20, and I48.21, effective 10/01/2019.
06/12/2020: Policy reviewed. Policy statements unchanged. Code Reference section updated to remove deleted CPT codes 33282 and 33284.
10/01/2020: Code Reference section updated to add CPT code 93298 and HCPCS code G2066. Removed deleted ICD-10 diagnosis codes I48.1 and I48.2.
12/17/2020: Code Reference section updated to add new CPT codes 93241, 93242, 93243, 93244, 93245, 93246, 93247, and 93248, effective 01/01/2021.
06/18/2021: Code Reference section updated to add new CPT code 0650T, effective 07/01/2021.
07/26/2021: Policy description updated regarding devices. Second medically necessary policy statement criteria updated to add "atrial." Policy Guidelines updated to change "Nervous/Mental Conditions" to "Mental Health Disorders" and "Medically Necessary" to "medical necessity."
06/07/2022: Policy description updated. Policy statements and Policy Guidelines updated to change "patients" to "individuals." Policy intent unchanged. Code Reference section updated to remove deleted CPT codes 0295T, 0296T, 0297T, and 0298T.
09/21/2022: Code Reference section updated to add new ICD-10 diagnosis codes I47.20, I47.21, and I47.29, effective 10/01/2022.
06/05/2023: Policy reviewed. Policy statement updated to change "patients" to "individuals."
09/29/2023: Code Reference section updated to add new ICD-10 diagnosis codes I47.10, I47.11, and I47.19, effective 10/01/2023.
12/21/2023: Code Reference section updated to make note of deleted HCPCS code.
06/11/2024: Policy description updated regarding devices. Policy statements unchanged. Code Reference section updated to remove deleted ICD-10 diagnosis code I47.2.
12/03/2025: Policy reviewed; no changes.
Blue Cross Blue Shield Association Policy #2.02.08
This may not be a comprehensive list of procedure codes applicable to this policy.
The code(s) listed below are ONLY medically necessary if the procedure is performed according to the "Policy" section of this document.
Covered Codes
Code Number | Description | ||
CPT-4 | |||
33285 | Insertion, subcutaneous cardiac rhythm monitor, including programming | ||
33286 | Removal, subcutaneous cardiac rhythm monitor | ||
93228 | Wearable mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; physician review and interpretation with report | ||
93229 | Wearable mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; technical support for connection and patient instruction for use, attended surveillance, analysis and physician prescribed transmission of daily and emergent data reports | ||
93241 | External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation | ||
93242 | External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording) | ||
93243 | External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; scanning analysis with report | ||
93244 | External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation | ||
93245 | External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation | ||
93246 | External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording) | ||
93247 | External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; scanning analysis with report | ||
93248 | External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | ||
93268 | Wearable patient activated electrocardiographic rhythm derived event recording with presymptom memory loop, per 30 day period of time; includes transmission, physician review and interpretation Note: This represents a bundled CPT code including all components of AEM monitoring, including EKG analysis of all the recorded strips during a 30-day period. | ||
93270 | Wearable patient activated electrocardiographic rhythm derived event recording with presymptom memory loop, 24-hour attended monitoring, per 30 day period of time; recording (includes connection, recording, and disconnection) | ||
93271 | Wearable patient activated electrocardiographic rhythm derived event recording with presymptom memory loop, 24-hour attended monitoring, per 30 day period of time; monitoring, receipt of transmissions, and analysis | ||
93272 | Wearable patient activated electrocardiographic rhythm derived event recording with presymptom memory loop, 24-hour attended monitoring, per 30 day period of time; physician review and interpretation only | ||
93298 | Interrogation device evaluation(s), (remote) up to 30 days; subcutaneous cardiac rhythm monitor system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional | ||
0650T | Programming device evaluation (remote) of subcutaneous cardiac rhythm monitor system, with iterative adjustment of the implantable device to test the function of the device and select optimal permanently programmed values with analysis, review and report by a physician or other qualified health care professional | ||
HCPCS | |||
G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results (Deleted 12/31/2023) | ||
E0616 | Implantable cardiac event recorder with memory, activator and programmer | ||
ICD-9 Procedure | ICD-10 Procedure | ||
0JWT0FZ | Revision of subcutaneous defibrillator lead in trunk subcutaneous tissue and fascia, open approach | ||
0JWT3FZ | Revision of subcutaneous defibrillator lead in trunk subcutaneous tissue and fascia, percutaneous approach | ||
37.79 | Revision or relocation of cardiac device pocket | 0JWT0PZ | Revision of cardiac rhythm related device in trunk subcutaneous tissue and fascia, open approach |
0JWT3PZ | Revision of cardiac rhythm related device in trunk subcutaneous tissue and fascia, percutaneous approach | ||
ICD-9 Diagnosis | ICD-10 Diagnosis | ||
426.9 | Unspecified conduction disorder | I45.9 | Conduction disorder, unspecified |
I47.10 | Supraventricular tachycardia, unspecified (New 10/01/2023) | ||
I47.11 | Inappropriate sinus tachycardia, so stated (New 10/01/2023) | ||
I47.19 | Other supraventricular tachycardia (New 10/01/2023) | ||
427.0 | Paroxysmal supraventricular tachycardia | I47.1 | Supraventricular tachycardia (Deleted 09/30/2023) |
427.1 | Paroxysmal ventricular tachycardia | I47.20, I47.21, I47.29 | Ventricular tachycardia |
427.2 | Paroxysmal tachycardia, unspecified | I47.9 | Paroxysmal tachycardia |
427.31 | Atrial fibrillation | I48.0, I48.11, I48.19, I48.20, I48.21, I48.91 | Atrial fibrillation |
427.32 | Atrial flutter | I48.3, I48.4, I48.92 | Atrial flutter |
427.41 | Ventricular fibrillation | I49.01 | Ventricular fibrillation |
427.42 | Ventricular flutter | I49.02 | Ventricular flutter |
427.60 | Premature beats, unspecified | I49.40 | Unspecified premature depolarization |
427.61 | Supraventricular premature beats | I49.1 | Atrial premature depolarization |
427.69 | Premature beats, other | I49.3 | Ventricular premature depolarization |
I49.49 | Other premature depolarization | ||
427.81 | Sinoatrial node dysfunction | I49.5 | Sick sinus syndrome |
427.89 | Other specified cardiac dysrhythmias | I49.8 | Other specified cardiac arrhythmias |
427.9 | Cardiac dysrhythmia, unspecified | I49.9 | Cardiac arrhythmia, unspecified |
I63.89 | Other cerebral infarction | ||
434.91 | Unspecified cerebral artery occlusion with cerebral infarction | I63.9 | Cerebral infarction, unspecified |
780.2 | Syncope and collapse | R55 | Syncope and collapse |
780.32 | Complex febrile convulsions | R56.01 | Complex febrile convulsions |
780.4 | Dizziness | R42 | Dizziness and giddiness |
785.0 | Tachycardia, unspecified | R00.0 | Tachycardia, unspecified |
785.1 | Palpitations | R00.2 | Palpitations |
CPT copyright American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.